HIV Infections
Conditions
Keywords
Functional cure of HIV， ASC22，PD-1
Brief summary
In HIV-infected patients, enhanced PD-1 expression of T cells correlates with T cell depletion, as evidenced by reduced virus-specific proliferative capacity and decreased cytokine expression.Targeting PD-L1 drugs to block PD-1/PD-L1 signaling may promote the secretion of antiviral cytokines and achieve HIV clearance.The mechanism of action of ASC22 is to competitively block the binding of PD-1 molecules to PD-L1 through its antigen-binding region with a high affinity for hPD-L1, thereby stimulating an innate or adaptive immune response with sustained T-cell activation.This study was conducted to evaluate whether ASC22 combined with chidamide in HIV-infected patients with antiviral suppression could shrink the viral reservoir.
Interventions
DRUGASC22 group
The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
Sponsors
Shanghai Public Health Clinical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. People diagnosed with HIV infection. 2. Age ≥18 years. 3. In good general health with a body mass index ≥18.0 to \<35.0 kg/m2. 4. Able to comply with the time requirements for study visits and assessments. 5. Currently on cART for at least 24 months with two consecutive plasma HIV-1 RNA \< 50 copies/ml at least 12 months apart. 6. CD4+ T-cell count ≥ 250 cells/µl (including borderline values) and CD4/CD8 \< 0.9 during the screening period. 7. Agree to adhere to contraception during participation in the project and for 6 months after completion of the trial. 8. Willing to sign the informed consent form.
Exclusion criteria
1. Subjects who have had any serious acute illness within 8 weeks. 2. Subjects with a history of active autoimmune disease or autoimmune disease requiring systemic therapy. 3. Pre-treatment/exposure to any other immune checkpoint inhibitors \[e.g., anti-programmed cell death protein 1 (PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.\]. 4. The patient has been treated with 1. Received previous treatment with other anti-submarine drugs within 30 days prior to enrollment. 2. Received radiotherapy or chemotherapy 30 days prior to screening. 3. Received immunosuppressive therapy 60 days prior to screening. 4. Treatment with immunomodulators (e.g., interleukins, interferons), hydroxyurea, or phosphonates 60 days prior to screening. 5. HIV vaccine or systemic cytotoxic chemotherapy 60 days prior to screening. 6. Prior immunoglobulin (IgG) therapy. 7. Previous blood transfusion or cell growth factor therapy 90 days prior to screening. 8. Use of rifampicin, rifabutin, etc. at the time of screening or during the planned treatment phase. 5. Laboratory tests meet the following criteria. 1. absolute neutrophil count (ANC) \<1.50×109/L; hemoglobin (Hb) \<105 g/L (male) or \<95 g/L (female); platelets \<75×10\^9/μ L; international normalized ratio (INR) \>1× upper limit of normal (ULN). 2. Serum alanine aminotransferase (SGPT/ALT) \>1.5× upper limit of normal (ULN), serum aspartate aminotransferase (SGOT/AST) \>1.5× upper limit of normal (ULN), total bilirubin, direct bilirubin \>1.5× upper limit of normal (ULN), serum creatinine \>1.5× upper limit of normal (ULN) × upper limit of normal value (ULN). 3. Five abnormal thyroid functions with clinical significance: tests include triiodothyronine (T3), tetraiodothyronine (T4), free triiodothyronine (FT3), free tetraiodothyronine (FT3), free tetraiodothyronine (FT4), and thyroid stimulating hormone (TSH). 4. Abnormal and clinically significant adrenaline tests, which must include at least ACTH and cortisol. Abnormal and clinically significant blood glucose and glycated hemoglobin. 6. Abnormal and clinically significant twelve-lead ECG at the time of enrollment. 7. Subjects with interstitial changes on chest CT at the time of enrollment. 8. Subjects with severe cardiac disease, symptomatic or asymptomatic arrhythmias. 9. Patients with co-infection with HBV, HCV, syphilis, etc., patients with diabetes mellitus, and patients with other liver diseases. 10. Subjects with a history of active or suspected malignancy or malignant disease (except basal cell skin cancer or in situ cervical cancer) within five years. 11. Subjects with a history of tuberculosis or active tuberculosis. 12. Subjects with psychiatric or substance abuse disorders known to interfere with study requirements. 13. Subjects who have received immunomodulation or immunosuppression within 24 weeks prior to the first dose of study drug (including any dose of IV/oral \[PO\] steroids, but excluding steroids by inhalation, topical, or by local injection) within 24 weeks prior to the first dose of the study drug. 14. Pregnant and lactating women, or men and women who intend to conceive a child during the study period. 15. Psychiatric patients or those whose substance abuse interferes with the conduct of the trial. 16. Histone deacetylase inhibitors, such as valproate, butyrate, and phenylbutyrate, but may be enrolled after a 28-day elution period. 17. Patients with severe cardiac insufficiency \[New York Heart Association (NYHA) Cardiac Insufficiency Classification Class IV\]. 18. Any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, within 6 months prior to enrollment; normatively treated uncontrolled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); cardiomyopathy 19. Patients with significant QT/QTC interval during the screening period (Fridericia formula. (19) Patients with a significant prolongation of the QT/QTC interval (Fridericia formula: QTcF=QT/RR0.33) during the screening period (e.g., repeated measurements showing a QTc interval \>450 ms, or another risk of torsional ventricular tachycardia \[TdP\] \[e.g., heart failure, hypokalemia, familial long QT syndrome\]) or combination of drugs that may cause prolongation of the QT/QTc interval. (20) Known allergy or anti-drug antibodies to drugs or excipients used in this trial. (21) Those who are judged by the investigator to be unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HIV-1 DNA levels | 52 weeks | Change in HIV-1 DNA levels from baseline at each cycle of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CD4+ T-cell count, CD4+ T-cell percentage, CD8+ T-cell count, CD4+/CD8+ ratio | 52 weeks | Changes in CD4+ T-cell count, CD4+ T-cell percentage, CD8+ T-cell count, CD4+/CD8+ ratio, and change from baseline at each cycle of treatment |
| HIV gag-specific CD8+ T ratio | 52 weeks | Change from baseline in HIV gag-specific CD8+ T ratio at each cycle of treatment |
| HIV-1 RNA | 52 weeks | Change in HIV-1 RNA from baseline at each cycle of treatment |
Other
| Measure | Time frame | Description |
|---|---|---|
| Treatment-Emergent Adverse Events | 52 weeks | All adverse events occurred after drug administration |
Countries
China
Contacts
Primary ContactJun Chen, M.D
Backup ContactShanghai Public Health Clinical Center Chen, M.D
Outcome results
None listed